A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion)

Key facts

Study ID

NCT00550017

Run by

Bristol-Myers Squibb

People needed

39

Starts

2007-12-01

Expected to finish

2010-03-01

Last updated by the study team

2015-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced cancer, excluding cancer in the blood
• Availability of 10 tumor tissue slides

You may not qualify if…

• Known brain metastases
• Severe nerve damage
• Significant cardiovascular disease
• Inadequate blood counts
• Inadequate liver or kidney function
• Inadequate thyroid function or uncontrolled thyroid disease

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States
• Local Institution — Ottawa, Ontario, Canada
• Local Institution — Toronto, Ontario, Canada
• Local Institution — Newcastle upon Tyne, Tyne and Wear, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.